Dekkers CCJ, et al. - In a broad population of patients with T2D, researchers compared the impacts of the sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and described the impacts of dapagliflozin on ePV. To calculate changes in ePV, the Strauss formula was utilized. In 10 patients with T2D randomized to dapagliflozin 10 mg/d or placebo, change in plasma volume measured with 125I-human serum albumin (mPV) was contrasted with change in ePV. Changes in ePV were subsequently measured in a pooled database of 13 phase 2b/3 placebo-controlled clinical trials including 4,533 patients with T2D who were randomized to 10 mg of dapagliflozin daily or matched placebo. The median change in ePV during dapagliflozin treatment was similar to the median change in mPV. Dapagliflozin reduced ePV by 9.6% vs placebo after 24 weeks in the pooled analysis of clinical trials. In various subgroups of patients, including subgroups with or without diuretic use or established cardiovascular disease, this effect was consistent. During dapagliflozin treatment, ePV may be used as a proxy to evaluate changes in plasma volume. In a broad population of patients with T2D, dapagliflozin consistently reduced ePV vs placebo.